Synonym
VU0364572 TFA salt; 1240514-89-9; VU0364572 (trifluoroacetate salt); AKOS037643457
IUPAC/Chemical Name
ethyl (R)-3-(2-methylbenzamido)-[1,4'-bipiperidine]-1'-carboxylate 2,2,2-trifluoroacetate
InChi Key
QEFQJTFXOBPBLZ-UNTBIKODSA-N
InChi Code
InChI=1S/C21H31N3O3.C2HF3O2/c1-3-27-21(26)23-13-10-18(11-14-23)24-12-6-8-17(15-24)22-20(25)19-9-5-4-7-16(19)2;3-2(4,5)1(6)7/h4-5,7,9,17-18H,3,6,8,10-15H2,1-2H3,(H,22,25);(H,6,7)/t17-;/m1./s1
SMILES Code
O=C(N1CCC(N2C[C@H](NC(C3=CC=CC=C3C)=O)CCC2)CC1)OCC.O=C(O)C(F)(F)F
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
487.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Digby GJ, Utley TJ, Lamsal A, Sevel C, Sheffler DJ, Lebois EP, Bridges TM,
Wood MR, Niswender CM, Lindsley CW, Conn PJ. Chemical modification of the M(1)
agonist VU0364572 reveals molecular switches in pharmacology and a bitopic
binding mode. ACS Chem Neurosci. 2012 Dec 19;3(12):1025-36. doi:
10.1021/cn300103e. Epub 2012 Sep 9. PMID: 23259038; PMCID: PMC3526969.
2: Weikop P, Jensen KL, Thomsen M. Effects of muscarinic M1 receptor
stimulation on reinforcing and neurochemical effects of cocaine in rats.
Neuropsychopharmacology. 2020 Nov;45(12):1994-2002. doi:
10.1038/s41386-020-0684-1. Epub 2020 Apr 28. PMID: 32344426; PMCID: PMC7547714.
3: Lebois EP, Schroeder JP, Esparza TJ, Bridges TM, Lindsley CW, Conn PJ, Brody
DL, Daniels JS, Levey AI. Disease-Modifying Effects of M1 Muscarinic
Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. ACS
Chem Neurosci. 2017 Jun 21;8(6):1177-1187. doi: 10.1021/acschemneuro.6b00278.
Epub 2017 Mar 7. PMID: 28230352; PMCID: PMC5808561.
4: Lebois EP, Trimper JB, Hu C, Levey AI, Manns JR. Effects of Selective
M1 Muscarinic Receptor Activation on Hippocampal Spatial
Representations and Neuronal Oscillations. ACS Chem Neurosci. 2016 Oct
19;7(10):1393-1405. doi: 10.1021/acschemneuro.6b00160. Epub 2016 Aug 12. PMID:
27479319.
5: Galloway CR, Lebois EP, Shagarabi SL, Hernandez NA, Manns JR. Effects of
selective activation of M1 and M4 muscarinic receptors on object recognition
memory performance in rats. Pharmacology. 2014;93(1-2):57-64. doi:
10.1159/000357682. Epub 2014 Jan 25. PMID: 24480931.
